Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer

被引：0

作者：

Bryony Alderman

David Hui

Sandip Mukhopadhyay

Carole Bouleuc

Amy A. Case

Koji Amano

Gregory B. Crawford

Giulia de Feo

Andrea Sbrana

Kimberson Tanco

Josephine To

Jessica Garsed

Mellar Davis

机构：

[1] Frimley Park Hospital,Department of Palliative Care

[2] Phyllis Tuckwell Hospice Care,Department of Palliative Care, Rehabilitation and Integrative Medicine

[3] University of Texas MD Anderson Cancer Center,Department of Supportive and Palliative Care

[4] Indian Council of Medical Research – National Institute of Cholera and Enteric Disease,Department of Palliative Medicine

[5] PSL University,Adelaide Medical School

[6] Institut Curie,Supportive Care in Cancer Unit

[7] Department of Palliative and Supportive Care,Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine

[8] Roswell Park Comprehensive Cancer Center,Division of Aged Care, Rehabilitation and Palliative Care

[9] Division of Geriatrics and Palliative Medicine University at Buffalo Jacobs School of Medicine and Biomedical Sciences,undefined

[10] National Cancer Center Hospital,undefined

[11] Northern Adelaide Palliative Service,undefined

[12] University of Adelaide,undefined

[13] Fondazione IRCCS,undefined

[14] Istituto Nazionale Dei Tumori,undefined

[15] Onco-Haematology,undefined

[16] University of Pisa,undefined

[17] Northern Adelaide Local Health Network,undefined

[18] Geisinger Medical Center,undefined

[19] Palliative Care Department,undefined

[20] Geisinger Medical System,undefined

来源：

Supportive Care in Cancer | 2023年 / 31卷

关键词：

MASCC ; Cannabinoids; Gastrointestinal symptoms;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 153 条

[1]

Bridgeman MB(2017)Medicinal cannabis: history, pharmacology, and implications for the acute care setting P T 42 180-188

[2]

Abazia DT(2016)Medical marijuana use in oncology: a review JAMA Oncol 2 670-675

[3]

Wilkie G(1975)Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy N Engl J Med 293 795-797

[4]

Sakr B(1979)Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation Ann Intern Med 91 819-824

[5]

Rizack T(1979)delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo Vet Hum Toxicol 21 338-340

[6]

Sallan SE(1981)A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy Cancer 47 1746-1751

[7]

Zinberg NE(1979)Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo Ann Intern Med. 91 825-830

[8]

Frei E(1982)Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine Cancer 50 636-645

[9]

Chang AE(1981)Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine J Clin Pharmacol 21 76S-80S

[10]

Shiling DJ(1988)Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy Invest New Drugs 6 243-246

← 1 2 3 4 5 6 7 8 9 10 →